Tongue Neoplasms: Clinical Trials

121 trials for Tongue Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

69 completed, 15 unknown, 11 terminated, 10 recruiting. 46 Phase 2, 29 Not applicable, 29 Phase 1, 10 Phase 3, 2 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 246Completed 33, Terminated 4, Unknown 4, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1, Suspended 1
Not applicable29Completed 10, Recruiting 7, Unknown 6, Terminated 3, Withdrawn 2, Active not recruiting 1
Phase 129Completed 21, Terminated 3, Withdrawn 2, Not yet recruiting 1, Recruiting 1, Suspended 1
Phase 310Completed 5, Active not recruiting 2, Unknown 2, Withdrawn 1
Early Phase 12Terminated 1, Unknown 1
Phase 41Completed 1

Follow Tongue Neoplasms: new trials by email Literature Review of Tongue Neoplasms trials Research Report on Tongue Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
Phase 1 / Phase 2Not yet recruitingWashington University School of Medicine452026-11-302026-11-03
Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
Ultrasound imaging, Standard Treatment - Tongue Cancer, Oral Cancer
Not applicableRecruitingTobias Todsen1502025-09-152026-05-13
High-Resolution PET-CT Imaging for Surgical Margin Visualization
Intra-op PET/CT Specimen Scanner - Cancer, Solid Malignant Tumors
Not applicableRecruitingVanderbilt-Ingram Cancer Center502025-09-032026-05-08
Normative Ranges of Lingual Strength and Endurance and the Impact of the IOPI Lingual Strength Trainer on Quantitative Functional Outcomes and Patient-Reported Outcomes After Partial Glossectomy or Hemiglossectomy for Oral Tongue Cancer, An Unblinded: Randomized Pilot Study
Iowa Oral Performance Instrument (IOPI) - Tongue Cancer
Not applicableRecruitingMemorial Sloan Kettering Cancer Center602025-08-072026-06-30
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
Panitumumab IRDye 800 - HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity
Phase 1RecruitingVanderbilt-Ingram Cancer Center702025-04-172026-08-03
Submental Island Flap vs Radial Forearm Free Flap in Tongue Reconstruction
Submental Island Pedicled Flap (SIPF), Radial Forearm Free Flap (RFFF) - Tongue Carcinoma, Tongue Neoplasms
CompletedAl-Azhar University282024-09-012026-09-15
Assessment of the Effect of Tumor Thickness and Site on Level IV Cervical Lymph Nodes in Squamous Cell Carcinoma of the Tongue and Floor of the Mouth: A Case Series Study
removal of primary tumor, neck dissection - Tongue Neoplasms
Not applicableUnknownCairo University202024-04-012024-05-29
Anterolateral Thigh Myofascial Fat Composite Flap for Reconstruction of Hemiglossectomy Defects in Obese Patients With Tongue Cancer
The anterolateral femoral myofascial fat composite flap (ALT-MF) repairs tongue defects in patients with tongue cancer - Tongue Cancer
Active not recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University352023-05-152026-07-06
Arabic PRO Measures for Head and Neck Cancer Radiotherapy.
Radiation - Head and Neck Cancer, Head and Neck Neoplasms
RecruitingKing Saud University1252023-05-012024-10-29
Surgical Margin Assessment by 3D Ultrasound
3D ultrasound - Tongue Cancer, Squamous Cell Carcinoma
Not applicableUnknownCopenhagen University Hospital, Rigshospitalet72023-01-012023-02-23
Use of ST250 to Reconstruct Lateral Tongue Defects
Tongue Neoplasms
CompletedCairo University102022-07-012025-05-23
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) - Skin Cancer, Mucosal Neoplasm of Oral Cavity
Not applicableTerminatedAlpha Tau Medical LTD.22021-07-082025-12-08
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
Best Practice, Medical Device Usage and Evaluation - Head and Neck Carcinoma, Malignant Parotid Gland Neoplasm
Phase 2Active not recruitingM.D. Anderson Cancer Center882021-05-262026-10-06
The Registry of Oncology Outcomes Associated With Testing and Treatment
Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P) - Adenocarcinoma, Adenocystic Carcinoma
CompletedTaproot Health1672021-05-052024-12-18
Clinical Study Evaluating the Proper Surgical Safety Margin for Early Stage Oral Tongue Cancers
1.5 cm surgical safety margin for cT1-2N0 oral tongue cancers, 1.0 cm surgical safety margin for cT1-2N0 oral tongue cancers - Tongue Cancer, Tongue Cancer TNM Staging Primary Tumor (T) T1
Not applicableTerminatedSamsung Medical Center1252021-01-182025-05-18
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) - Skin Cancer, Mucosal Neoplasm of Oral Cavity
Not applicableCompletedAlpha Tau Medical LTD.22020-12-222025-12-02
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) - Skin Cancer, Mucosal Neoplasm of Oral Cavity
Not applicableRecruitingAlpha Tau Medical LTD.562020-12-222026-06-16
Radio/Pathological Evaluation of Tongue Cancer Infiltration
Radiologic and pathological review. - Oral Squamous, Cell Carcinoma
UnknownHospices Civils de Lyon2002020-11-272021-03-29
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) - Skin Cancer, Mucosal Neoplasm of Oral Cavity
Not applicableRecruitingAlpha Tau Medical LTD.302020-10-212025-12-02
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
QBS10072S - Astrocytoma, Brain Cancer
Phase 1CompletedQuadriga Biosciences, Inc.152020-07-202023-01-18

Showing 20 of 121. Sign in to see all of them.

Narrower conditions

Squamous Cell Carcinoma of Head and Neck (76)  ·  Head and Neck Neoplasms (47)  ·  Salivary Gland Neoplasms (39)  ·  Mouth Neoplasms (31)  ·  Oropharyngeal Neoplasms (16)  ·  Laryngeal Neoplasms (15)  ·  Carcinoma, Squamous Cell (14)  ·  Hypopharyngeal Neoplasms (14)  ·  Carcinoma, Non-Small-Cell Lung (13)  ·  Nasopharyngeal Neoplasms (12)  ·  Esthesioneuroblastoma, Olfactory (11)  ·  Colonic Neoplasms (10)  ·  Breast Neoplasms (9)  ·  Esophageal Neoplasms (9)

Broader conditions

Mouth Diseases (121)  ·  Neoplasms by Site (121)  ·  Stomatognathic Diseases (121)  ·  Tongue Diseases (121)  ·  Neoplasms (113)  ·  Mouth Neoplasms (90)  ·  Neoplasms by Histologic Type (89)  ·  Neoplasms, Glandular and Epithelial (89)  ·  Carcinoma (85)  ·  Head and Neck Neoplasms (74)  ·  Carcinoma, Squamous Cell (66)  ·  Salivary Gland Diseases (40)  ·  Respiratory Tract Diseases (26)  ·  Otorhinolaryngologic Diseases (25)  ·  Respiratory Tract Neoplasms (23)

Interventions

Cetuximab (16)  ·  Cisplatin (16)  ·  Radiotherapy, Intensity-Modulated (11)  ·  Docetaxel (7)  ·  Radiotherapy (7)  ·  Erlotinib Hydrochloride (5)  ·  Fluorouracil (5)  ·  Carboplatin (4)  ·  Everolimus (4)  ·  130-nm albumin-bound paclitaxel (3)  ·  Albumin-Bound Paclitaxel (3)  ·  Biopsy (3)  ·  Chemotherapy, Adjuvant (3)  ·  Fluorodeoxyglucose F18 (3)  ·  Paclitaxel (3)

Sponsors

National Cancer Institute (NCI) (20)  ·  Alpha Tau Medical LTD. (5)  ·  Fox Chase Cancer Center (5)  ·  Ohio State University Comprehensive Cancer Center (5)  ·  Memorial Sloan Kettering Cancer Center (4)  ·  Roswell Park Cancer Institute (4)  ·  Alliance for Clinical Trials in Oncology (3)  ·  Cairo University (3)  ·  Radiation Therapy Oncology Group (3)  ·  University of Chicago (3)  ·  Centre Antoine Lacassagne (2)  ·  European Organisation for Research and Treatment of Cancer - EORTC (2)  ·  Fuda Cancer Hospital, Guangzhou (2)  ·  GERCOR - Multidisciplinary Oncology Cooperative Group (2)  ·  Rutgers, The State University of New Jersey (2)

Countries

United States (73)  ·  France (8)  ·  Canada (7)  ·  China (7)  ·  United Kingdom (6)  ·  Israel (4)  ·  India (3)  ·  Italy (3)  ·  Saudi Arabia (3)  ·  Denmark (2)  ·  Egypt (2)  ·  Germany (2)  ·  South Africa (2)  ·  South Korea (2)  ·  Sweden (2)

Top investigators

Anurag Singh (2)  ·  Barbara Burtness (2)  ·  Jill Gilbert (2)  ·  Sung Kim (2)  ·  Tanguy Seiwert (2)  ·  Ahmed Elkhadem, PhD (1)  ·  Alexander Langerman (1)  ·  Amit Agrawal (1)  ·  Amit Agrawal, MD (1)  ·  Andrea L. Pusic, MD, MHS (1)  ·  Anna Lee (1)  ·  Aron Popovtzer (1)  ·  Aron Popovtzer, M.D (1)  ·  Barry Ziober, PhD (1)

Results publications

PMID 25057165, PMID 14520092, PMID 17985341, PMID 19372041, PMID 19602035, PMID 19735988, PMID 21367608, PMID 21917515, PMID 22252927, PMID 23188068, PMID 23639862, PMID 24182765, PMID 24733799, PMID 25684313, PMID 25965900, PMID 26062933, PMID 26611425, PMID 26928328, PMID 28029303, PMID 29149611, PMID 29346519, PMID 30768363, PMID 30850872, PMID 31405750, PMID 31611612, PMID 31618129, PMID 33507809, PMID 35945244, PMID 36537851, PMID 37650478, PMID 39841939, PMID 39868569, PMID 40166973, PMID 42185750, PMID 42289363

NIH funding

U10CA021115 (3), N01CM62201 (2), P30CA014599 (2), P30CA072720 (2), U01CA062502 (2), U10CA032102 (2), U10CA180868 (2), N01CM00032 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62202 (1), N01CM62206 (1), P30CA006516 (1), P30CA006927 (1)